An example of this is the successful application of the combination of DFMO (difluoromethyl ornithine, a specific irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme of polyamine biosynthesis) and a polyamine uptake inhibitor AMXT 1501 for the treatment of neuroblastoma (https://www.ccia.org.au/our-impact/a-new-treatment-for-neuroblastoma). This evidence concerns the gene ODC1 and neuroblastoma.